DUBLIN–(BUSINESS WIRE)–The “Global Biosimulation – Market and Technology Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.
The overall global market size of the Biosimulation segment accounts for roughly USD 4 Billion in 2020 and it is expected to reach a value of approximately USD 9 Billion by 2028 with a CAGR of 11%.
The growing investment in R&D for the biosimulation market is one of the key factors that has been influencing its market growth. Another factor that propels the growth of this market is the growing pharmaceutical industry and the use of advanced technological tools in this sector. Owing to the use of this software, the cost incurred during the production of drugs has reduced considerably.
The growth of the biosimilars market as well as the biologics market is another factor that impacts this market positively. This report helps with the analysis of the value chain for this market and further quantifies the end-user segments with respect to market growth. To analyse the growth of this sector, this report is segmented with respect to End-User, Application, and Region.
North America leads the global market due to its increased R&D funding in the fields of biotechnology and pharmaceuticals respectively. Moreover, North America has an infrastructure and IT services that promote research in this field and further helps with optimising the existing technology.
Based on the forward integration, the pharmaceutical and biotechnology segment has the largest market value this is due to the use of this technology to give solutions from a predetermined database for biological problems. This feature of biosimulation supports its use in the manufacture of drugs and helps cut costs before the development stage itself. Based on the product & service segment- the software segment is the fastest-growing market.
One of the key applications of biosimulation is in the field of pharmaceutical toxicology, it is a field associated with chemical, pharmaceutical, and biological properties of drug-induced agents produced to treat human diseases. It is a multidisciplinary platform that deals with scientific, clinical, and regulatory approaches aimed at the prediction and management of hazards related to pharmaceutical drugs. Biosimulation helps quantify this data and saves time concerning clinical experiments performed in terms of toxicology studies.
This report is aimed at:
- Key drivers, restraints, and challenges along with their effect on the changing market trends globally have been provided.
- The high growth sectors of the biosimulation market have been studied in the opportunities chapter.
- An analysis of the key players of this market and the strategies employed by them have been covered.
- The forecast period of this report ranges from 2020-2028, therefore all the events that have had an impact on the changing market scenario have been discussed.
- Porter’s 5 forces and PESTLE Analysis has been done to strategically analyze this market.
Segmentation in this report
By End-User
- Pharmaceutical & Biotechnology Companies
- Regulatory Authorities
- Research Institutes
- Contract Research Organization
- Others
By Application:
- Drug Development
- Drug Discovery
- Others
By Product
- Software
-
Services
- In-house Services
- Contract Services
Country Analysis:
- United States
- Canada
- France
- Germany
- Spain
- Portugal
- Denmark
- Netherlands
- Sweden
- Finland
- United Kingdom
- Switzerland
- Italy
- Japan
- Israel
- Turkey
- Australia
- China
- Malaysia
- Brazil
For more information about this report visit https://www.researchandmarkets.com/r/ybz5un
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900